Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Arterial Occlusive Diseases » Arteriosclerosis » Atherosclerosis » Peripheral Arterial Disease
Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Peripheral Vascular Diseases » Peripheral Arterial Disease
Description
Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less. MeSH
Hierarchy View
Subtype Terms (2)
Chronic Limb-Threatening Ischemia
70 drugs (26 approved, 44 experimental)
Intermittent Claudication
57 drugs (27 approved, 30 experimental)
Approved Indicated Drugs (3)
Phase 4 Indicated Drugs (33)
Phase 3 Indicated Drugs (26)
Phase 2 Indicated Drugs (47)
Phase 1 Indicated Drugs (14)
Other Experimental Indicated Drugs (38)
Organization Involved with Phase 4 Indications (77)
Arteriogenesis Competence Network
Barnsley Hospital NHS Foundation Trust
Federation of Associations of Hospital Doctors on Internal Medicine (FADOI) Foundation
Hoosier Cancer Research Network
Los Angeles Biomedical Research Institute
National Heart, Lung, and Blood Institute (NHLBI)
Shin Kong Wu Ho-Su Memorial Hospital
Taipei Veteran General hospital
Tung's Taiching MetroHarbor Hospital
University of Alabama, Birmingham
University of California, Los Angeles
University of California, San Francisco
Organization Involved with Phase 3 Indications (69)
Asheville Cardiology Associates
Beijing Northland Biotech. Co., Ltd.
Brazilian Clinical Research Institute
Canadian Institutes of Health Research (CIHR)
Heart and Stroke Foundation of Canada
Human Stem Cell Institute, Russia
Icahn School of Medicine at Mount Sinai
Omrix Biopharmaceuticals, Inc.
SMT KASHIBAI NAVALE MEDICAL COLLEGE
The University of Texas, Dallas
Organization Involved with Phase 2 Indications (96)
Aiyan Diabetes Center, Evans, GA
Cardiovascular Cell Therapy Research Network
Chinese Academy of Medical Sciences
Etablissement Français du Sang
Granzer Regulatory Consulting & Services
Institut National de la Santé Et de la Recherche Médicale, France
MultiGene Vascular Systems Ltd.
National Center for Complementary and Integrative Health (NCCIH)
National Institute on Aging (NIA)
National Institutes of Health (NIH)
Oregon Health and Science University
Saint-Petersburg State Medical University
Organization Involved with Phase 1 Indications (16)
Organization Involved with Other Experimental Indications (27)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.